Ondansetron-<wbr/><sup>13</sup>C-d<sub>3</sub>

Ondansetron-13C-d3

CAT N°: 25754
Price:

From 343.00 291.55

Ondansetron-13C-d3 is intended for use as an internal standard for the quantification of ondansetron by GC- or LC-MS. Ondansetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3 receptor (Ki = 1.6 nM).{23962} It is selective for the 5-HT3 receptor over the 5-HT1A-D, 5-HT2, and 5-HT4 receptors (Kis = >1,200 nM). It inhibits 5-HT-induced depolarization of isolated rat vagus nerve and contraction of isolated guinea pig ilium longitudinal muscle-myenteric plexus preparations in a concentration-dependent manner ex vivo.{45010} In a ferret model of cisplatin-induced emesis, ondansetron reduces the number of retching and vomiting episodes and increases the latency time to vomit when administered at a dose of 0.01 mg/kg and eliminates retching and vomiting when administered at a dose of 0.1 mg/kg.{45011} Ondansetron (0.5 and 1 mg/kg) also decreases immobility time in a forced swim test and increases time spent in the light chamber and latency to leave the light chamber in the light/dark exploration test in a mouse model of diabetes induced by streptozotocin (STZ; Item No. 13104), indicating antidepressant-like and anxiolytic activities.{45012} Formulations containing ondansetron have been used in the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, or following surgery.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 9-(methyl-13C-d3)-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one
  • Correlated keywords
    • 1132757-82-4 99614-02-5 5HT 5HT1A 5HT1D 5HT2 5HT3 5HT4 deuterated deuterium GCMS LCMS GR 38032F NSC 665799 GR38032F NSC665799 anti-depressant
  • Product Overview:
    Ondansetron-13C-d3 is intended for use as an internal standard for the quantification of ondansetron by GC- or LC-MS. Ondansetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3 receptor (Ki = 1.6 nM).{23962} It is selective for the 5-HT3 receptor over the 5-HT1A-D, 5-HT2, and 5-HT4 receptors (Kis = >1,200 nM). It inhibits 5-HT-induced depolarization of isolated rat vagus nerve and contraction of isolated guinea pig ilium longitudinal muscle-myenteric plexus preparations in a concentration-dependent manner ex vivo.{45010} In a ferret model of cisplatin-induced emesis, ondansetron reduces the number of retching and vomiting episodes and increases the latency time to vomit when administered at a dose of 0.01 mg/kg and eliminates retching and vomiting when administered at a dose of 0.1 mg/kg.{45011} Ondansetron (0.5 and 1 mg/kg) also decreases immobility time in a forced swim test and increases time spent in the light chamber and latency to leave the light chamber in the light/dark exploration test in a mouse model of diabetes induced by streptozotocin (STZ; Item No. 13104), indicating antidepressant-like and anxiolytic activities.{45012} Formulations containing ondansetron have been used in the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, or following surgery.

We also advise you